Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2019 Feb 20

PMID 30776883

Citations 18

Authors

Hyo Song Kim

Chung Mo Nam

Suk-Yong Jang

Sun Kyu Choi

Minkyung Han

Seonmin Kim

Maria Victoria Moneta

Sae Young Lee

Jae Min Cho

Diego Novick

Sun Young Rha

Affiliations

Soon will be listed here.

Abstract

Purpose: A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status.

Materials And Methods: The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases.

Results: A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis.

Conclusion: This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.

Citing Articles

Long Q, Li Z, Yang W, Huang K, Du G J Cancer Res Clin Oncol. 2024; 150(4):203.

PMID: 38635069 PMC: 11026213. DOI: 10.1007/s00432-024-05682-w.

Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study.

Jang Y, Jeong H, Kong C, Song W, Cho W, Jeon D Oncol Lett. 2024; 27(5):211.

PMID: 38572064 PMC: 10988193. DOI: 10.3892/ol.2024.14344.

First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial.

Li T, Dong Y, Wei Y, Wang S, Liu Y, Chen J Clin Cancer Res. 2024; 30(19):4310-4317.

PMID: 38483309 PMC: 11443219. DOI: 10.1158/1078-0432.CCR-23-3983.

Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.

Mochizuki T, Ikegami M, Akiyama T Cancer Sci. 2023; 115(2):575-588.

PMID: 38115234 PMC: 10859616. DOI: 10.1111/cas.16050.

Identification of mC-related molecular subtypes and prediction models in the prognosis and tumor microenvironment infiltration of soft tissue sarcoma.

Wang X, Mao Y, Xu H, Chen J, Chen X Heliyon. 2023; 9(9):e19680.

PMID: 37809908 PMC: 10558950. DOI: 10.1016/j.heliyon.2023.e19680.

References

Gustafson P . Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 1994; 259:1-31. View

Krikelis D, Judson I . Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010; 10(2):249-60. DOI: 10.1586/era.09.176. View

Hoang H, Ensor K, Rosen G, Pachter H, Raccuia J . Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma. Int J Surg Oncol. 2014; 2014:919323. PMC: 4090477. DOI: 10.1155/2014/919323. View

Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Baerentzen S, Pedersen A, Keller J . Prevalence and prognostic impact of comorbidity in soft tissue sarcoma: a population-based cohort study. Acta Oncol. 2014; 53(9):1188-96. DOI: 10.3109/0284186X.2014.888494. View

Corless C, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P . PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005; 23(23):5357-64. DOI: 10.1200/JCO.2005.14.068. View

Toro J, Travis L, Wu H, Zhu K, Fletcher C, Devesa S . Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006; 119(12):2922-30. DOI: 10.1002/ijc.22239. View

Italiano A, Mathoulin-Pelissier S, Cesne A, Terrier P, Bonvalot S, Collin F . Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2010; 117(5):1049-54. DOI: 10.1002/cncr.25538. View

Kang S, Kim H, Choi E, Han I . Incidence and Treatment Pattern of Extremity Soft Tissue Sarcoma in Korea, 2009-2011: A Nationwide Study Based on the Health Insurance Review and Assessment Service Database. Cancer Res Treat. 2015; 47(4):575-82. PMC: 4614194. DOI: 10.4143/crt.2014.047. View

Ogura K, Higashi T, Kawai A . Statistics of soft-tissue sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci. 2017; 22(4):755-764. DOI: 10.1016/j.jos.2017.03.017. View

10.

Bae S, Crowe P, Gowda R, Joubert W, Carey-Smith R, Stalley P . Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res. 2016; 6:11. PMC: 4939824. DOI: 10.1186/s13569-016-0052-4. View

11.

Bray F, Ferlay J, Laversanne M, Brewster D, Gombe Mbalawa C, Kohler B . Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015; 137(9):2060-71. DOI: 10.1002/ijc.29670. View

12.

Casali P, Blay J . Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v198-203. DOI: 10.1093/annonc/mdq209. View

13.

Judson I, Verweij J, Gelderblom H, Hartmann J, Schoffski P, Blay J . Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15(4):415-23. DOI: 10.1016/S1470-2045(14)70063-4. View

14.

Ray-Coquard I, Collard O, Ducimetiere F, Laramas M, Mercier F, Ladarre N . Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). BMC Cancer. 2017; 17(1):111. PMC: 5297166. DOI: 10.1186/s12885-017-3057-3. View

15.

Seong S, Kim Y, Khang Y, Park J, Kang H, Lee H . Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016; 46(3):799-800. PMC: 5837262. DOI: 10.1093/ije/dyw253. View

16.

Sheng J, Movva S . Systemic Therapy for Advanced Soft Tissue Sarcoma. Surg Clin North Am. 2016; 96(5):1141-56. DOI: 10.1016/j.suc.2016.06.006. View

17.

Yang L, Fang Z, Fan Z, Wang N, Yuan Y, Li H . [An analysis of incidence trends and characteristics of soft tissue sarcoma in Beijing, 1999-2013]. Zhonghua Zhong Liu Za Zhi. 2017; 39(6):471-476. DOI: 10.3760/cma.j.issn.0253-3766.2017.06.013. View

18.

Tap W, Jones R, Van Tine B, Chmielowski B, Elias A, Adkins D . Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043):488-97. PMC: 5647653. DOI: 10.1016/S0140-6736(16)30587-6. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

20.

Wibmer C, Leithner A, Zielonke N, Sperl M, Windhager R . Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol. 2009; 21(5):1106-11. DOI: 10.1093/annonc/mdp415. View